乳腺癌患者血清可溶性Fas、FasL水平的检测

Changes and Significance of Serum Soluble Fas(sFas) and FasL(sFasL) Levels in Patients with Breast Cancer

目的探讨乳腺癌患者血清可溶性Fas(sFas)、可溶性FasL(sFasL)水平的变化及临床意义。方法采用酶联免疫吸附法(ELISA)检测54例乳腺癌患者,20例乳腺良性病变者,18例正常健康志愿者血清中sFas、sFasL的含量,分析两者与乳腺癌临床病理参数的相关性及临床治疗对它们的影响。结果乳腺癌患者血清sFas、sFasL水平高于两对照组,Ⅲ+Ⅳ期高于Ⅰ+Ⅱ期,治疗后低于治疗前(P均<0.05),sFas、sFasL与其他临床病理参数无显著相关性,两对照组血清sFas、sFasL水平无显著性差异(P>0.05)。结论sFas、sFasL可能与乳腺癌的免疫逃逸有关,可作为乳腺癌新的肿瘤标志物。

ObjecUve To study the changes and function of serum soluble Fas（sFas） and FasL（sFasL） levels in patients with breast cancer. Methods Enzyme-linked imrnunosorbent assay （ELISA） was available to detect the levels of serum sFas and sFasL in 54 patients with breast cancer,20 patients with benign breast tumors and 18 normal healthy donors, analysis the correlation both of them and the clinical pathological parameters of breast cancer, the changes both of them by clinical treatments. Results Serum sFas and sFasL levels in breast cancer group were significantly higher than those of the two control groups, patients of stage Ⅲ and Ⅳ were significantly higher than those of patients of stage Ⅰand Ⅱ,the values of post-treatments were remarkably reduced compare with pre-treatments（P〈0. 05）, no significant correlations were found both of them and the other clinical pathological parameters of breast cancer, serum sFas and sFasL levels of the two control groups showed no significant difference（P〉0. 05）. Conclusion Serum sFas and sFasL may serve as novel tumor markers for breast cancer, both of them may participate in the mechanism through which breast cancer cells escape from the immune attack.